Characterization of macular neovascularization subtypes in nAMD to optimize treatment outcomes

My guest for this episode is Professor Nicole Eter, Professor of Ophthalmology and Chair of the Department of Ophthalmology at the University of Münster, Germany. In this episode, Nicole and I chat about the different macular neovascularization (MNV) subtypes, discussing the diagnostic tools used to classify MNV subtypes, their defining characteristics and variants, and the impact of these on our patients.
Our conversation highlights why it’s important to tailor treatment to MNV subtype for our patients to have the best outcomes, and the significance of discussing lesions, prognoses and treatments with patients and their caregivers. Important resources, such as the Vision Academy Viewpoint on MNV subtypes and treatment algorithms and educational slide decks, can be found on the https://www.visionacademy.org/. Or can be downloaded directly from here; view point and slide deck. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.

If you enjoyed this episode, SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here at: https://www.amdbarometer.org/resources

Speaker disclosures:
Professor Anat Loewenstein
Consultancy: Allergan, Annexon, Bayer, Beyeonics, Biogen, ForSight Labs, Iqvia, Iveric Bio, Johnson & Johnson, MJHEvents, Nanoretina, Notal Vision, Novartis, Ocuphire Pharma, Ocuterra, Ophtimedrx, Ripple Therapeutics, Roche, Syneos, WebMD, and Xbrane.
Professor Nicole Eter
Consultancy: Alcon, Allergan, Apellis, Bayer, Novartis, and Roche; Payments/honoraria: Allergan, Apellis, Bayer, Novartis, and Roche; Research grants: Bayer and Novartis; Support for meetings/travel: Roche.

Further information on other studies mentioned in this episode:
Mathis T, et al. Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye. 2022. https://www.nature.com/articles/s41433-022-02231-y
Spaide RF, et al. Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. 2020. https://www.sciencedirect.com/science/article/pii/S0161642019322432
November 2023 MA-PFM-OPHT-ALL-1182-1

This podcast series is intended for HCPs, and is not intended for UK audiences.

This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.
The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.

The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.